RxDoctor Payments Data

Azamuddin Khaja, MD

Interventional Cardiology · Farmington, MONPI 1699723486

Payments from drug & device makers

$21,485in general payments, 2019–2025

Across 986 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$3K
  • Amgen$2K
  • Medtronic$2K
  • Johnson & Johnson$2K
  • Philips North America LLC$1K
  • Boston Scientific$1K
  • plus $11K from 42 others

What the payments were for

  • Travel & lodging$1,6618%
  • Food & beverage$19,82492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,485 in reported general payments places this provider in the 60th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$445,963
Medicare patients
692
Services billed
2,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban426$375,703
EntrestoSacubitril/Valsartan294$289,027
FarxigaDapagliflozin Propanediol255$204,950
XareltoRivaroxaban241$203,746
Repatha SureclickEvolocumab289$202,944
AdempasRiociguat14$194,727
OpsumitMacitentan12$153,985
JardianceEmpagliflozin106$122,930
KerendiaFinerenone34$36,174
OzempicSemaglutide33$35,693
VerquvoVericiguat46$32,732
BrilintaTicagrelor53$29,297
Praluent PenAlirocumab38$24,524
VascepaIcosapent Ethyl42$16,845
TrulicityDulaglutide13$11,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$375,703426 claims
NovartisEntresto$1,231$289,027294 claims
AstraZenecaFarxiga, Brilinta$940$234,247308 claims
BayerAdempas, Kerendia$1,017$230,90148 claims
Johnson & JohnsonXarelto$1,713$203,746241 claims
Actelion Pharmaceuticals US, Inc.Opsumit$1,268$153,98512 claims
Boehringer IngelheimJardiance, Pradaxa$979$125,132117 claims
Novo NordiskOzempic$78$35,69333 claims
MerckVerquvo$424$32,73246 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$80$8,86529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Farmington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →